A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : CENU / chloroethylnitrosourea

[Related PubMed/MEDLINE]
Total Number of Papers: 30
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   CENU  (>> Co-occurring Abbreviation)
Long Form:   chloroethylnitrosourea
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Chloroethylating anticancer drug-induced mutagenesis and its repair in Escherichia coli. AGT, ICLs, MMR, NER
2010 A model of phospholipid biosynthesis in tumor in response to an anticancer agent in vivo. ODEs, PEMT
2009 Combined methionine deprivation and chloroethylnitrosourea have time-dependent therapeutic synergy on melanoma tumors that NMR spectroscopy-based metabolomics explains by methionine and phospholipid metabolism reprogramming. Met
2009 Mitochondrial bioenergetic background confers a survival advantage to HepG2 cells in response to chemotherapy. OXPHOS
2008 Chemotherapy-induced bystander effect in response to several chloroethylnitrosoureas: an origin independent of DNA damage? ---
2007 PP2A activity is controlled by methylation and regulates oncoprotein expression in melanoma cells: a mechanism which participates in growth inhibition induced by chloroethylnitrosourea treatment. PP2A
2006 Bystander effects are induced by CENU treatment and associated with altered protein secretory activity of treated tumor cells: a relay for chemotherapy? cHsp, PEBP, ROS
2006 Clinical response of O(6)-methylguanine-DNA methyltransferase levels to 1,3-(2-chloroethyl)-1-nitrosourea chemotherapy in glioma patients. GBMs, TTP
2005 Long-term disease-free survival in advanced melanomas treated with nitrosoureas: mechanisms and new perspectives. ---
10  2003 Quantitative HRMAS proton total correlation spectroscopy applied to cultured melanoma cells treated by chloroethyl nitrosourea: demonstration of phospholipid metabolism alterations. HR-MAS, PLP, TOCSY
11  2000 Development of a syngenic brain-tumor model resistant to chloroethyl-nitrosourea using a methylguanine DNA methyltransferase cDNA. MGMT
12  1999 Acquired resistance to O6-benzylguanine plus chloroethylnitrosoureas in human breast cancer. BBR, BCNU, CNU
13  1999 N-(2-chloroethyl)-N-nitrosourea tethered to lexitropsin induces minor groove lesions at the p53 cDNA that are more cytotoxic than mutagenic. lex, N3-Alkyl-As
14  1999 Relationship between O6-methylguanine-DNA methyltransferase levels and clinical response induced by chloroethylnitrosourea therapy in glioma patients. GBMs, MGMT, TTP
15  1999 Retroviral-mediated expression of the P140A, but not P140A/G156A, mutant form of O6-methylguanine DNA methyltransferase protects hematopoietic cells against O6-benzylguanine sensitization to chloroethylnitrosourea treatment. 6BG, WTMGMT
16  1997 Evidence for nucleotide excision repair as a modifying factor of O6-methylguanine-DNA methyltransferase-mediated innate chloroethylnitrosourea resistance in human tumor cell lines. BCNU, MGMT
17  1997 O6-methylguanine-DNA methyltransferase (MGMT) transfectants of a 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-sensitive colon cancer cell line selectively repopulate heterogenous MGMT+/MGMT- xenografts after BCNU and O6-benzylguanine plus BCNU. BCNU, BG, MGMT, V8MGMT
18  1996 Enhancement effect of O6-fluorobenzylguanines on chloroethylnitrosourea cytotoxicity in tumor cells. ACNU, MGMT
19  1996 Human brain tumor O(6)-methylguanine-DNA methyltransferase mRNA and its significance as an indicator of selective chloroethylnitrosourea chemotherapy. RT-PCR, TTP
20  1996 Wild-type p53 suppresses transcription of the human O6-methylguanine-DNA methyltransferase gene. MGMT
21  1995 The role of mRNA stability and transcription in O6-methylguanine DNA methyltransferase (MGMT) expression in Mer+ human tumor cells. MGMT, STZ
22  1994 Disposition and metabolism of O6-alkylguanine-DNA alkyltransferase inhibitor in nude mice bearing human melanoma. BNAG
23  1993 Activity and unexpected lung toxicity of the sequential administration of two alkylating agents--dacarbazine and fotemustine--in patients with melanoma. ARDS, DTIC, O6AT
24  1993 DNA crosslinking, sister chromatid exchange and cytotoxicity of N-2-chloroethylnitrosoureas tethered to minor groove binding peptides. SCE
25  1992 Modulation of BUdR labeling index in rat brain tumors following intracarotid ACNU administration. ACNU, BUdR, LI
26  1992 Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure. MTP
27  1990 Comparisons between sensitive and resistant human tumor cell lines regarding effects of polyamine depletion on chloroethylnitrosourea efficacy. BCNU, DFMO, ISC, PA, STZ
28  1989 Affinity purification and characterization of human O6-alkylguanine-DNA alkyltransferase complexed with BCNU-treated, synthetic oligonucleotide. ---
29  1988 Aerobic and hypoxic toxicity of a new class of mixed-function drugs associating nitroimidazoles and chloroethylnitrosourea in nitrosourea-sensitive (Mer-) and -resistant (Mer+) human tumor cells. NI, NI-CENU
30  1988 Formation of covalent complexes between human O6-alkylguanine-DNA alkyltransferase and BCNU-treated defined length synthetic oligodeoxynucleotides. BCNU